1 The EIC Accelerator Project
EIC Accelerator Program Overview
The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support innovative small and medium-sized enterprises (SMEs) and startups in Europe. This program aims to foster the development of breakthrough technologies and disruptive innovations that have the potential to create significant societal and economic impact. The EIC Accelerator offers a unique blend of grant funding and equity investment, empowering companies to scale their operations and attract further private sector investment.
Funding Structure
Under the EIC Accelerator, companies can receive blended finance, which consists of two components:
- Until 2024, eligible companies can receive equity investments of up to €15 million.
- From 2025 onwards, the maximum equity investment will be reduced to €10 million.
This dual funding mechanism enables companies to combine the benefits of non-dilutive funding with the opportunities presented by equity investment, thereby enhancing their capacity to grow and innovate.
Purpose and Impact
The primary purpose of the EIC Accelerator is to nurture the European DeepTech ecosystem and stimulate the startup environment. It is strategically positioned to support high-risk, high-reward projects that may struggle to secure funding from traditional markets due to their innovative nature. By bridging the funding gap early in the innovation cycle, the EIC Accelerator plays a crucial role in helping companies transition from concept to market-ready solutions.
The program also aims to enhance the competitiveness of European businesses on a global scale. By providing financial resources and strategic guidance, the EIC Accelerator fosters an environment where startups can thrive, attract private investments, and create jobs. The program emphasizes the importance of collaboration between public and private sectors, encouraging startups to develop partnerships that can amplify their impact.
IDOVEN 1903 SL and the WILLEM Project
Company Overview
IDOVEN 1903 SL is a Spanish company that has gained recognition for its innovative approach to healthcare technology. The company focuses on leveraging artificial intelligence to improve cardiovascular health outcomes, reflecting a commitment to addressing significant health challenges.
Project Description: WILLEM
The EIC Accelerator project, known as WILLEM (AI to Reduce Cardiovascular Diseases), was submitted by IDOVEN in October 2021. This project is centered around the development of an advanced artificial intelligence platform designed to enhance the detection, management, and prevention of cardiovascular diseases (CVD).
Technology Basics and Background
Cardiovascular diseases remain one of the leading causes of morbidity and mortality worldwide. The WILLEM project employs cutting-edge AI algorithms to analyze vast amounts of patient data, including electrocardiograms (ECGs) and other relevant health metrics. By harnessing machine learning techniques, the platform aims to identify patterns and anomalies that may indicate the presence of cardiovascular conditions.
The technology is grounded in the principles of predictive analytics and data-driven decision-making. It incorporates a robust database of historical patient records and outcomes, enabling the AI system to learn from past data and continuously improve its predictive capabilities. The ultimate goal of WILLEM is to provide healthcare professionals with actionable insights that can lead to timely interventions, thus reducing the incidence and impact of cardiovascular diseases.
Additionally, WILLEM aims to enhance patient engagement by creating a user-friendly interface that allows individuals to monitor their cardiovascular health proactively. This focus on patient empowerment is critical for improving health outcomes and fostering a culture of prevention.
In summary, the EIC Accelerator program serves as a vital catalyst for innovation in the European startup landscape. With its unique funding structure and strategic objectives, it supports pioneering projects like IDOVEN's WILLEM, which seeks to revolutionize cardiovascular healthcare through advanced AI technologies. The impact of such initiatives can lead to significant improvements in public health and contribute to the overall advancement of medical science.
2 The Funding Rounds
Financing Raised by IDOVEN 1903 SL
IDOVEN 1903 SL, a Spanish healthtech company specializing in AI-powered cardiology solutions, has experienced significant funding activity since winning the EIC Accelerator in October 2021. Below is a detailed overview of its financing history, funding rounds, investors, valuations, and exit event status.
Funding Rounds and Amounts
- Seed Round
- Timing: May 2021
- Amount: €2 million (approx. $2.4 million)
- Valuation: Pre-money valuation of €10 million
- Investors: Wayra (Telefónica's open innovation hub), Accel Partners (Accel Starters program), ENISA (Spanish public funding agency), top-level business angels including Iker Casillas.
- EIC Accelerator Grant & Equity Funding
- Timing: April–June 2022
- April: Announcement of EIC award (€6.5 million)
- June: Series A round announcement includes EIC portion ($6.9 million; roughly aligns with €6.5M at the time).
- Series A Round
- Timing: June 2022
- Amount Raised: $12.9 million
- Combined total for Series A + EIC support: $19.8 million
- Co-led by Insight Partners and Northzone; other participants include Wayra and several notable angel investors such as Ron Vianu (Covera Health), Vlad Lata (Avi Medical), existing angels like Iker Casillas, Diego Piacentini and Sebastian Gunningham.
- Additional Funding
- In September 2023, basketball legend Pau Gasol joined as an investor in a new round led by Northzone with follow-on investment from Insight Partners and previous major investors.
Summary Table of Funding Rounds
| Date | Round/Type | Amount | Lead Investors/Participants | Notable Details |
|---|---|---|---|---|
| May 2021 | Seed | €2M (~$2.4M) | Accel Partners, Wayra, ENISA | Pre-money valuation: €10M |
| Apr–Jun 2022 | Grant/Equity | €6.5M ($6.9M) | European Innovation Council Accelerator | Part of combined Series A package |
| Jun 2022 | Series A | $12.9M | Insight Partners & Northzone | Total round including grants: $19.8M |
| Sep 2023 | Add-on Investment | Undisclosed | Northzone (+Insight Partners; Pau Gasol etc.) | |
| Apr 2024 Project Grant |
Key Investors
Other notable former senior executives involved include Diego Piacentini and Sebastian Gunningham from Apple/Amazon backgrounds.
Company Valuations
The only publicly disclosed valuation is from the seed round in May 2021—a pre-money valuation of €10 million. No official updates on subsequent post-money or later-stage valuations have been made public.
Exit Events
There are no reports or evidence indicating that IDOVEN has undergone an IPO or been acquired/bought out as of April 23rd April 23rd 2025 ―the company remains privately held.
Summary
Since receiving the EIC Accelerator award in late‑ October¶‚¤²²¹¹²¹²¹²¹₂₁₂₁₂₁₂₁₂₁₂₁₂₁2121, IDOVEN has raised at least ~$22–24+ million across various equity rounds and grants/grant-equity hybrids—primarily aimed at accelerating product development for its AI cardiology platform while building out its international footprint through both private venture capital investment and substantial European grant support. No exits have occurred to date.
Sources:
- Idoven raises $19.8m funding to redefine detection...
- IDOVEN closes a EUR two-million financing round...
- IDOVEN receives EUR six-point-five-million from EIC...
3 The Press Releases
Idoven 1903 SL: Advances in AI-Driven Cardiovascular Care
Idoven 1903 SL, a Spanish company specializing in AI-powered cardiovascular care, received funding from the European Innovation Council (EIC) Accelerator in October 2021. Since then, Idoven has made significant strides in advancing the field of cardiology through innovative AI technologies.
Technology and Partnerships
- AI-Powered ECG Analysis: Idoven's flagship technology includes WILLEM, a cloud-based AI software designed to analyze electrocardiograms (ECGs) and diagnose cardiac arrhythmias. This technology has been integrated into various medical systems, including implantable cardiac monitors (ICMs) in partnership with Abbott, a leading medical device company.
- NVIDIA DGX Systems Acquisition: In July 2024, Idoven acquired NVIDIA DGX H100 systems, enhancing its AI infrastructure to accelerate the training and validation of AI models. This acquisition aims to improve the accuracy and efficiency of cardiovascular disease diagnosis by enabling faster processing of large datasets.
- Collaborations and Partnerships: Idoven collaborates with leading medical device and pharmaceutical companies to develop a new standard of cardiovascular care. Notable partnerships include the pan-European MAESTRIA Consortium, which involves collaboration with multiple European and U.S. research centers to develop integrative diagnostic digital platforms.
Funding and Investments
- EIC Accelerator Funding: Idoven received $6.9 million in grant and equity funding from the EIC Accelerator in 2021 as part of a broader funding round.
- Series A Funding Round: In June 2022, Idoven raised $19.8 million, including a $12.9 million Series A round co-led by Insight Partners and Northzone. This funding supports the development of Idoven's AI platform and accelerates its mission to advance early detection and precision medicine for cardiovascular diseases.
- Recent Investments: Basketball legend Pau Gasol has joined Iker Casillas in investing in Idoven, highlighting the company's growing influence in AI-driven cardiology.
Team Updates and Impact
- Influential Backers: Idoven's investor list includes former senior executives from Apple and Amazon, along with prominent figures from the sports world like Iker Casillas and Pau Gasol. This diverse support underscores the company's potential to revolutionize cardiovascular care.
- Global Impact: Idoven's AI solutions are transforming cardiac diagnosis and care delivery worldwide. Their technology is being used in hospitals across Finland and is expanding to other specialties like neurology.
Press Releases and Updates
Idoven regularly updates its website with news on partnerships, technological advancements, and funding rounds. Recent press releases highlight collaborations with Abbott in Finnish hospitals and the acquisition of NVIDIA DGX systems to enhance AI capabilities.
Conclusion
Since receiving EIC Accelerator funding in October 2021, Idoven has significantly advanced its AI-driven cardiovascular care solutions. The company continues to expand its partnerships, enhance its technology with cutting-edge AI infrastructure, and attract influential investors.
Sources: - Idoven | AI-powered Cardiovascular Care
- About Us - Idoven
- Idoven Raises $19.8 Million in Funding
- Idoven Acquires NVIDIA DGX Systems
- Idoven 1903 SL - ARISTOTELES
- Pinsent Masons advises on the financing round of Idoven 1903
- Science Journals: Editorial Policies
- CNN Spotlights Idoven and Abbott’s Partnership
- News - Idoven
4 The Technology Advancements
Current Capabilities of IDOVEN 1903 SL
IDOVEN 1903 SL, a Spanish company, has developed a cloud-based AI software named Willem, which analyzes electrocardiograms (ECGs) to diagnose cardiac arrhythmias. They offer several cardiological services, including ECG reports for individuals, analysis of long-term Holters for hospitals, and ECG monitoring for patients at home. IDOVEN's platform is designed to enhance cardiologists' ability to identify, triage, and diagnose patients effectively by integrating with electronic health record systems and home monitoring devices.
Advancements Since EIC Accelerator Funding
Since receiving the EIC Accelerator funding in October 2021, IDOVEN has made significant advancements:
- Expansion of Arrhythmia Detection: IDOVEN's AI platform has been integrated with Abbott's ICM Confirm Rx device, increasing arrhythmia detection from 4 to 25 cardiac rhythm patterns. This integration achieved a 95.4% accuracy for arrhythmia classification and reduced false positives by 98%.
- NVIDIA DGX Systems Acquisition: IDOVEN acquired NVIDIA DGX systems to enhance its AI capabilities, allowing for faster and more accurate ECG analysis. This upgrade accelerates training and execution of AI models, reducing processing times and enhancing diagnostic processes.
- FAITHFUL Project: EIT Health funded the FAITHFUL project with €1.7 million, led by IDOVEN, to develop a solution for early detection of heart failure using advanced algorithms and AI applied to ECGs.
Technology Improvements and Market Demonstrations
IDOVEN has demonstrated its technology through collaborations and clinical trials:
- Clinical Trials: IDOVEN is involved in clinical trials using its Willem software for AI-powered ECG analysis in high-risk cardiac patients, aiming to automate the classification and prediction of cardiac arrhythmic episodes.
- Partnerships: The company partners with leading medical device and pharmaceutical companies to innovate in cardiovascular care. For instance, their collaboration with Abbott has shown significant improvements in arrhythmia detection.
New Patents or Scientific Studies
IDOVEN has published several studies highlighting the effectiveness of its AI platform:
- Publication in Journals: The company has published papers in the Cardiovascular Digital Health Journal and the Journal of Electrocardiology, showcasing the enhanced diagnostic capabilities of its AI technology.
- Research Collaborations: IDOVEN is part of the MAESTRIA Consortium, focusing on developing digital platforms for diagnosing atrial fibrillation and preventing stroke.
Sources: - Idoven | AI-powered Cardiovascular Care
- Idoven Named to the 2023 CB Insights' Digital Health 50 List
- Idoven's AI Platform improves arrhythmia detection in ICMs from 4 to ...
- AI-powered ECG Analysis Using Willem Software in High-risk Cardiac Patients
- idoven 1903 sl
- EIT Health funds the FAITHFUL project with €1.7M led by Idoven to ...
- Idoven acquires NVIDIA DGX systems to advance its mission of ...
- 117 years ago IDOVEN was born thanks to Willem Einthoven
- IDOVEN receives EUR 6.5 million in funding from the European Innovation Council
- Basketball Legend Pau Gasol joins Healthtech Scaleup Idoven in a ...
5 The Partnerships and Customers
IDOVEN 1903 SL, a Spanish AI-powered cardiovascular care company, has built and expanded significant partnerships and customer relationships since receiving EIC Accelerator funding in October 2021. These collaborations have strengthened its market position, enhanced technology advancements, and supported scaling efforts.Partnerships and Customers
- New or Notable Partnerships
- In July 2021, IDOVEN signed a collaboration agreement with Sanitas Hospitales to offer cardiology services via the Sanitas Health Portal. This partnership aims to provide remote cardiology services to more patients by integrating IDOVEN’s AI-driven ECG analysis into Sanitas’ digital health offerings.
- Telefónica is a key partner providing equipment provision expertise alongside investment support through Wayra; this includes housing and maintaining NVIDIA DGX systems acquired by IDOVEN to accelerate AI algorithm training for cardiovascular disease diagnosis.
- The company is also an active member of the pan-European MAESTRIA Consortium alongside other leading European research centers such as University of Oxford (UK), CNIC Spain (National Center for Cardiovascular Research), Siemens Healthcare Germany among others. This consortium develops integrative diagnostic platforms targeting atrial fibrillation detection using machine learning approaches where IDOVEN contributes with cutting-edge digital ECG analysis expertise.
- Celebrity Investors & Ambassadors
Nature & Purpose of Relationships
These partnerships serve multiple strategic purposes:
- Technology Advancement: Collaborations with NVIDIA enable access to high-performance computing infrastructure critical for training deep learning models at scale that power their WILLEM cloud-based AI software analyzing ECGs from various devices ranging from wearables to hospital-grade equipment.
- Scaling Clinical Reach: Agreements with healthcare providers like Sanitas allow deployment of remote cardiac monitoring services directly accessible by patients across Europe. Corporate clients such as Google or sports organizations like Real Madrid Foundation integrate these tools into wellness programs enhancing early detection capabilities at large population scales.
- Research & Innovation: Membership in MAESTRIA Consortium facilitates joint development of novel algorithms that predict atrial fibrillation progression leveraging diverse clinical datasets collected across European centers—helping establish new standards in cardiac diagnostics augmented by AI methods developed by IDOVEN researchers combined with expert collaborators’ input from academia and industry partners alike.
Market Positioning Impact
These relationships position IDOVEN distinctly within the cardiovascular digital health space:
- They elevate IDOVEN’s brand visibility through association with renowned global companies (Google, AstraZeneca) plus elite sports entities which signals trustworthiness and innovation leadership.
- Participation in transnational research consortia highlights scientific credibility while accelerating regulatory acceptance pathways important for wider adoption.
- Strategic investments combined with technical partnerships enable rapid scale-up capability internationally beyond Spain ensuring competitive advantage over fragmented market players focusing only on local solutions.
How Relationships Help Technology Advancement & Scaling
The combination of clinical collaborations plus tech infrastructure investments powers continuous improvement of their AI platform:
- Access to diverse real-world ECG data sets through hospital partners fuels robust model training improving diagnostic performance covering multiple arrhythmias under varied conditions.
- High-end NVIDIA DGX systems accelerate algorithm development cycles reducing time-to-market for new features enabling faster response against emerging clinical needs.
- Integration into established healthcare portals ensures seamless physician workflow augmentation thereby increasing adoption rates while generating valuable usage data creating virtuous feedback loops supporting iterative product refinement.
In summary,
Since winning EIC Accelerator funding in October 2021, IDOVEN has strategically allied itself with major healthcare institutions like Sanitas Hospitales; global corporations including Google; medical device manufacturers such as Abbott; research consortia spanning Europe; investors including Pau Gasol; and tech firms like NVIDIA/Telefónica—all serving technological advancement ambitions focused on scalable AI-enhanced cardiology diagnostics delivered remotely at population scale. These relationships collectively strengthen its market positioning as a leader redefining cardiovascular disease detection globally through artificial intelligence-enabled precision medicine solutions.
Sources:
6 The Hiring and Company Growth
IDOVEN 1903 SL, a Spanish health technology company specializing in AI-powered cardiovascular care, has experienced significant team growth and strategic hiring since receiving EIC Accelerator funding in October 2021.Team Growth and Headcount
Following the award of €6.5 million from the European Innovation Council (EIC) Accelerator and additional funding rounds culminating in $19.8 million raised by mid-2022, Idoven has been aggressively expanding its workforce to support its ambitious goals. Although exact current headcount numbers are not publicly specified, information indicates rapid scaling with new hires focused on critical areas such as sales, regulatory affairs, machine learning and data engineering, marketing, and human resources.
Hiring Activity and Key Positions
Idoven’s recruitment drive is aimed at building a "digital cardiology dream team" to enhance their AI platform Willem for cardiovascular diagnostics. The company has actively opened positions across multidisciplinary fields combining data science expertise with medical knowledge to advance their cardiology-as-a-service offering. The recent acquisition of advanced NVIDIA DGX H100 AI supercomputing systems suggests an emphasis on hiring high-level AI researchers and engineers capable of leveraging this infrastructure for faster algorithm training and validation.
Impact of New Team Members on Company Growth
The influx of talent supports Idoven’s mission to scale up early detection capabilities for cardiac diseases using cloud-based AI that integrates with hospital systems worldwide. This expansion enables faster ECG interpretation at scale while improving diagnostic accuracy and remote patient monitoring—key factors that will help reduce healthcare costs globally. New hires accelerate product development cycles, regulatory approvals, market penetration efforts especially across Europe where they send ECG kits directly to citizens’ homes.
Management or Founding Team Changes
No major changes in management or founding members have been reported since the EIC funding win. Dr. Manuel Marina Breysse remains CEO & co-founder leading the company through this growth phase; his leadership is frequently cited as instrumental in driving technological innovation alongside clinical validation collaborations with hospitals and pharma companies.
In summary:
- Idoven has significantly grown its team size post-EIC funding through strategic hiring primarily in technical (AI/ML engineering), regulatory affairs, sales/marketing roles.
- Current headcount specifics are not publicly disclosed but described as rapidly expanding.
- Hiring new expert personnel supports scaling up their AI platform’s capability for global impact on cardiovascular disease diagnosis.
- No known major shifts in management; leadership continuity under CEO Manuel Marina Breysse ensures stability during growth.
- Investments into advanced computing infrastructure underpin a future-ready workforce able to accelerate innovation.
This robust staffing strategy aligns closely with Idoven's goal to revolutionize cardiac care through scalable artificial intelligence solutions.
Sources:
- idoven 1903 sl - ARISTOTELES
- Idoven | AI-powered Cardiovascular Care
- IDOVEN raises $19.8 million
- IDOVEN receives €6.5M from EIC
- Idoven acquires NVIDIA DGX systems
- Dun & Bradstreet IDOVEN profile
7 The Media Features and Publications
Overview of IDOVEN 1903 SL
IDOVEN 1903 SL, a Spanish company, received funding from the European Innovation Council (EIC) Accelerator in October 2021. The company specializes in leveraging artificial intelligence (AI) to revolutionize cardiovascular care, particularly in ECG interpretation and early detection of heart diseases.
Media Features and Publications
Since receiving the EIC funding, IDOVEN has been featured in several media outlets and publications. For instance, CNN highlighted Idoven's collaboration with Abbott in Finnish hospitals as part of the Tomorrow Transformed Series. Additionally, El Español mentioned Idoven among "the impact unicorns of tomorrow" in a feature on startups with significant social and environmental impact. The company has also been named on the Norrsken Impact/100 List 2024, which recognizes impactful startups globally. Moreover, The Objective published articles detailing Idoven's advanced algorithms for saving lives through cardiovascular disease diagnosis.
Podcasts and Interviews
While specific podcasts or interviews performed by the Idoven team are not detailed in the available search results, the company's involvement in media and its collaborations with well-known figures like Iker Casillas and Pau Gasol suggest active engagement with the public and media.
Conferences and Fair Participations
IDOVEN participates in collaborative research and has connections with leading EU and US research centers. However, specific details about recent conference visits or presentations are not provided in the search results.
Involvement in Events
IDOVEN is involved in various initiatives, including the #donateyourheartbeats movement aimed at advancing research in cardiovascular disease prevention. The company collaborates with influential figures like Iker Casillas to promote early detection and intervention of cardiovascular diseases, especially among vulnerable groups.
Funding and Development
Idoven raised $19.8 million in funding in June 2022 to enhance its AI platform for detecting arrhythmias and cardiac abnormalities. This includes a $12.9 million Series A round and $6.9 million in grant and equity funding from the European Innovation Council (EIC). The company has also invested in NVIDIA DGX systems to accelerate AI algorithm training and improve cardiovascular disease diagnosis.
Sources: - Idoven | AI-powered Cardiovascular Care
- News - Idoven
- About Us - Idoven
- IDOVEN 1903 SL - ARISTOTELES
- Idoven Raises $19.8 Million in Funding
- Idoven Acquires NVIDIA DGX Systems
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.